Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Acoramidis shows strong benefits in treating ATTR-CM, reducing heart failure and hospitalizations.
BBIO
$69.66
+$0.76 +1.10%

Acoramidis shows strong benefits in treating ATTR-CM, reducing heart failure and hospitalizations.

Company Fundamentals
11 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and outpatient worsening heart failure, showing early and sustained benefits. The Phase 3 ATTRibute-CM study demonstrated a 34% reduction in cardiovascular hospitalizations compared to tafamidis, with a favorable mortality trend and comparable safety. These results highlight acoramidis as a fast-acting, effective treatment option for ATTR-CM, approved in multiple regions, with ongoing data presentations planned.

More News (BBIO)

BridgeBio to present positive Phase 3 trial results of oral infigratinib for children with achondroplasia at ICCBH 2026.

BridgeBio to present positive Phase 3 trial results of oral infigratinib for children with achondroplasia at ICCBH 2026.

BridgeBio Pharma announced it will share additional positive data from its global Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia at the ICCBH 2026 conference in Montreal. The presentation will highlight the drug's potent...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App